These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 2117286

  • 21. [Immunological effect of recombinant interferon-gamma in renal cell carcinoma].
    Kawata N, Ono M, Endo M, Ichinose T, Hamada T, Hirano D, Fuse T, Takimoto Y.
    Hinyokika Kiyo; 1993 Jun; 39(6):511-5. PubMed ID: 8337976
    [Abstract] [Full Text] [Related]

  • 22. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ.
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [Abstract] [Full Text] [Related]

  • 23. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH.
    Cancer Res; 1990 Sep 01; 50(17):5414-20. PubMed ID: 2117482
    [Abstract] [Full Text] [Related]

  • 24. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Sep 01; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

  • 25. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA, Pierce WC, Belldegrun A.
    Semin Oncol; 1993 Dec 01; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract] [Full Text] [Related]

  • 26. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR, Sznol M.
    Semin Oncol; 1995 Feb 01; 22(1):61-6. PubMed ID: 7855620
    [No Abstract] [Full Text] [Related]

  • 27. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec 01; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Preliminary findings on clinical and immunological effects of subcutaneously administered interleukin-2 + alpha-interferon combination in the treatment of advanced renal carcinoma].
    Buda F, Buda C, Croatto T, Costa B, Aragona P, Tuveri G.
    Recenti Prog Med; 1995 Dec 01; 86(7-8):304-5. PubMed ID: 7569288
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effects of interleukin-2 treatment on CD1d-restricted natural killer T cells.
    Sandberg JK, Moll M.
    Clin Cancer Res; 2007 Jul 15; 13(14):4311; author reply 4311-2. PubMed ID: 17634562
    [No Abstract] [Full Text] [Related]

  • 32. Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma.
    Marumo K, Muraki J, Ueno M, Tachibana M, Deguchi N, Baba S, Jitsukawa S, Hata M, Tazaki H.
    Urology; 1989 Mar 15; 33(3):219-25. PubMed ID: 2784018
    [Abstract] [Full Text] [Related]

  • 33. [Properties of LAK cell activity and LAK-generation in PBL isolated from patients with renal cell carcinoma].
    Hayakawa M, Hatano T, Koyama Y, Masuda T, Higa I, Osawa A.
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep 15; 79(9):1497-503. PubMed ID: 3266646
    [No Abstract] [Full Text] [Related]

  • 34. Renal cell carcinoma and interleukin-2: a review.
    Wagstaff J, Baars JW, Wolbink GJ, Hoekman K, Eerenberg-Belmer AJ, Hack CE.
    Eur J Cancer; 1995 Sep 15; 31A(3):401-8. PubMed ID: 7540404
    [No Abstract] [Full Text] [Related]

  • 35. Interleukin 2 induced cytotoxicity on renal cell carcinoma. 1. In vitro enhancement of natural killer cell activity.
    Ueno M.
    Keio J Med; 1986 Jun 15; 35(2):80-9. PubMed ID: 3097369
    [No Abstract] [Full Text] [Related]

  • 36. [The immunotherapy of advanced renal cell carcinoma].
    Bergmann L, Weidmann E, Mitrou PS.
    Dtsch Med Wochenschr; 1991 Mar 08; 116(10):384-90. PubMed ID: 1705879
    [No Abstract] [Full Text] [Related]

  • 37. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma.
    Lau BH, Ruckle HC, Botolazzo T, Lui PD.
    Cancer Biother; 1994 Mar 08; 9(2):153-61. PubMed ID: 7812364
    [Abstract] [Full Text] [Related]

  • 38. Interleukin-2: sunrise for immunotherapy?
    Lancet; 1989 Feb 11; 1(8633):308. PubMed ID: 2563463
    [No Abstract] [Full Text] [Related]

  • 39. Treatment of metastatic melanoma and renal cell carcinoma with interleukin-2.
    Manson LA.
    JAMA; 1994 Nov 02; 272(17):1327. PubMed ID: 7933390
    [No Abstract] [Full Text] [Related]

  • 40. [Bacteremia caused by Streptococcus equisimilis in a neoplastic patient treated with recombinant interleukin 2].
    Pedro-Botet ML, Ribelles Entrena N, Carrasco Miserachs I, Carles Galcerán J, Sabria-Leal M, Arnal J.
    Enferm Infecc Microbiol Clin; 1990 Dec 02; 8(10):659-60. PubMed ID: 2098130
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.